Marker Therapeutics, Inc.
MRKRDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
16dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Low dose FRα vaccine | Phase 2 | Breast Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Marker Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Marker Therapeutics, Inc.'s (MRKR) pipeline across Phase 2. Its lead program is Low dose FRα vaccine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Marker Therapeutics, Inc.'s next FDA catalyst?→
Marker Therapeutics, Inc.'s (MRKR) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRKR biotech catalysts?→
Add MRKR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Marker Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.